Literature DB >> 18625154

Evidence for benefits of angiotensin receptor blockade beyond blood pressure control.

Helmy M Siragy1.   

Abstract

Elevated levels of angiotensin II result in oxidative stress and endothelial dysfunction, which initiate atherogenic pathologic processes that are important in cardiovascular disease development. Angiotensin II induces its deleterious effects primarily through the type 1 receptor; these effects are inhibited by angiotensin II receptor blockers (ARBs) directly at the receptor level. Angiotensin II may potentiate protective mechanisms through stimulation of the type 2 receptor, which is not blocked by ARBs. Accumulating data suggest that blockade of angiotensin II production or activity provides vascular and cardioprotective benefits, such as reduction of atrial fibrillation, acute myocardial infarction, and heart failure events. Moreover, blockade of the renin-angiotensin system has been shown to offer renal protection in subjects with and without diabetes mellitus and to reduce the risk of new-onset diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625154     DOI: 10.1007/s11906-008-0050-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Angiotensin AT1 and AT2 receptors--the battle for health and disease.

Authors:  Helmy M Siragy
Journal:  Nephrol Dial Transplant       Date:  2007-10-19       Impact factor: 5.992

2.  Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.

Authors:  Ajay K Gupta; Bjorn Dahlof; Joanna Dobson; Peter S Sever; Hans Wedel; N R Poulter
Journal:  Diabetes Care       Date:  2008-01-30       Impact factor: 19.112

3.  Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.

Authors:  Chun Xue; Helmy M Siragy
Journal:  Hypertension       Date:  2005-07-25       Impact factor: 10.190

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.

Authors:  B López; R Querejeta; N Varo; A González; M Larman; J L Martínez Ubago; J Díez
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

6.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

7.  Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.

Authors:  Alaa S Awad; Randy L Webb; Robert M Carey; Helmy M Siragy
Journal:  J Hypertens       Date:  2004-08       Impact factor: 4.844

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 9.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  6 in total

Review 1.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

2.  Pharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor down-regulation in rat liver epithelial and aortic smooth muscle cells.

Authors:  Sivaramakrishna Koganti; Russell Snyder; Thomas Thekkumkara
Journal:  Gend Med       Date:  2012-02-25

Review 3.  Comparing angiotensin II receptor blockers on benefits beyond blood pressure.

Authors:  Helmy M Siragy
Journal:  Adv Ther       Date:  2010-06-03       Impact factor: 3.845

Review 4.  Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.

Authors:  Verdiana Ravarotto; Elisa Pagnin; Antonio Fragasso; Giuseppe Maiolino; Lorenzo A Calò
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-11

Review 5.  The intracellular renin-angiotensin system in the heart.

Authors:  Rajesh Kumar; Vivek P Singh; Kenneth M Baker
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

6.  Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.

Authors:  Glaucia E Callera; Tayze T Antunes; Jose W Correa; Danielle Moorman; Alexey Gutsol; Ying He; Aurelie Nguyen Dinh Cat; Ana M Briones; Augusto C Montezano; Kevin D Burns; Rhian M Touyz
Journal:  Biosci Rep       Date:  2016-10-27       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.